中国经济网北京9月23日讯百诚医药（301096）(301096.SZ)昨日晚间发布公告称，公司于近日收到董事 兼高级管理人员贾飞，董事宋博凡、严洪兵，高级管理人员陈安分别出具的《关于股份减持计划的告知 函》。 持有百诚医药股份48,908股(占百诚医药总股本比例0.0451%，总股本已剔除回购专户股份数777,300股， 下同)的贾飞计划自公告日起15个交易日后的3个月内通过集中竞价交易方式减持百诚医药股份不超过 12,200股，即不超过百诚医药目前总股本比例的0.0112%。 持有百诚医药股份9,337股(占百诚医药总股本比例0.0086%)的宋博凡计划自公告日起15个交易日后的3个 月内通过集中竞价交易方式减持百诚医药股份不超过2,300股，即不超过百诚医药目前总股本比例的 0.0021%。 2024年和2025年上半年，百诚医药实现归属于上市公司股东的净利润分别为-5274.28万元和309.82万 元，实现归属于上市公司股东的扣除非经常性损益的净利润分别为-7263.18万元和-1173.01万元。 百诚医药于2021年12月20日在深交所创业板上市，发行股票2704.17万股，发行价格为79.60 ...

Summary of Key Points Core Viewpoint - On September 22, a total of 29 A-share listed companies disclosed share reduction plans, indicating a trend of insider selling in the market [1]. Group 1: Companies with Share Reduction Plans - Kaidi Co., Ltd. plans to reduce its shares by no more than 380,300 shares [3]. - Rihai Intelligent's largest shareholder intends to reduce its stake by no more than 2.77% [3]. - Xilong Science's controlling shareholders plan to collectively reduce their shares by no more than 3% [3]. - Aopu Optoelectronics' controlling shareholder has completed its reduction plan [3]. - Rijiu Optoelectronics' controlling shareholder, Chen Xiaoli, plans to reduce no more than 3% of the company's shares [3]. - Demingli's controlling shareholder has completed its reduction plan [3]. - Zhongshe Co., Ltd.'s shareholder Chen Fengjun intends to reduce no more than 1% of the company's shares [3]. - Henghui Security's shareholders plan to collectively reduce no more than 2.34% of the company's shares [3]. - Debang Technology's National Integrated Circuit Industry Investment Fund recently reduced its stake by 0.65% [3]. - Chuangli Group's director and deputy general manager, Geng Weidong, plans to reduce no more than 0.6956% of the company's shares [3]. - Zhongdian Electric's shareholder Wang Jiankai intends to reduce no more than 3% of the company's shares [3]. - SF Express' shareholder Liu Jilu plans to transfer no more than 7 million A-shares to his son-in-law [3]. - Tianqin Equipment's shareholder Zhang Peng plans to reduce no more than 1% of the company's shares [3]. - Shuijing Optoelectronics' shareholder Shen Gai Zhen intends to reduce no more than 0.99% of the company's shares [3]. - Yingfite's controlling shareholder plans to reduce no more than 2.82% of the company's shares [3]. - Baicheng Medical's part of the board and supervisors plan to reduce their shares [3]. - Guangting Information's SAIC Venture Capital plans to transfer 3.16% of the company's shares to SAIC Group [3]. - Sihui Fushi's controlling shareholder and its concerted parties recently reduced a total of 385,200 shares [3]. - Baolong Technology's director Wang Shengquan plans to reduce no more than 0.11% of the company's shares [3]. - Saiwei Electronics' National Integrated Circuit Industry Investment Fund recently reduced a total of 6.3481 million shares [3]. - Rizhao Port's Shandong Energy plans to reduce no more than 3% of the company's shares [3]. - Xuelong Group's shareholder Ningbo Lianzhan plans to reduce no more than 1.95% of the company's shares [3]. - China Electric Research's shareholder Kaitian Investment plans to transfer 8.09 million shares [3]. - Lianxiang Co., Ltd.'s shareholders plan to reduce no more than 2.58% and 1.16% of the company's shares [3]. - Yingnuo Laser's shareholder reduction plan has been completed [3]. - Zhejiang Pharmaceutical's shareholder Guotou Gaoke plans to reduce no more than 1% of the company's shares [3]. - Dingyang Technology's shareholders plan to transfer 3.184 million shares, accounting for 2% of the total share capital [3]. - Sanyou Medical's shareholder QM5 LIMITED plans to transfer 6.67 million shares, accounting for 2% of the total share capital [3].

格隆汇9月22日丨百诚医药(301096.SZ)公布，为提高资金利用率，实现优质资产配置目标，杭州百诚医 药科技股份有限公司借助专业机构的专业力量，由公司控制的杭州觅鹏企业管理合伙企业（有限合伙） （简称"杭州觅鹏"）拟参与认购西湖创新（杭州）科创成果转化创业投资合伙企业（有限合伙）份额， 杭州觅鹏于2025年9月19日签署《合伙协议》。杭州觅鹏作为有限合伙人，拟以自有资金1,500万元认购 对应的出资额。投资方向：生物医药、硬科技等战略新兴产业。 ...

Summary of Key Points Core Viewpoint - Baicheng Pharmaceutical (301096.SZ) announced that several board members and senior management plan to reduce their shareholdings through centralized bidding within three months after 15 trading days from the announcement date [1] Group 1: Shareholding Reduction Plans - Director and senior executive Mr. Jia Fei plans to reduce his holdings by up to 12,200 shares, representing approximately 0.0112% of the company's total share capital [1] - Director Ms. Song Bofan intends to reduce her holdings by up to 2,300 shares, which is about 0.0021% of the company's total share capital [1] - Director Mr. Yan Hongbing plans to reduce his holdings by up to 9,500 shares, accounting for approximately 0.0088% of the company's total share capital [1] - Senior executive Mr. Chen An intends to reduce his holdings by up to 11,200 shares, representing around 0.0103% of the company's total share capital [1]

Group 1 - The core point of the article is that Baicheng Pharmaceutical plans to invest 15 million yuan in a private equity fund to enhance asset allocation and improve capital utilization [1] - The investment will be made through Hangzhou Mipeng Enterprise Management Partnership, which is controlled by the company, and the partnership agreement was signed on September 19, 2025 [1] - The investment aligns with the regulations of the Shenzhen Stock Exchange regarding transactions and related party transactions, as the private equity fund is related to the company's main business [1] Group 2 - As of the report, Baicheng Pharmaceutical has a market capitalization of 6.8 billion yuan [2] - For the first half of 2025, the company's revenue composition is as follows: CRO business accounts for 86.22%, commercial production accounts for 10.28%, and CDMO business accounts for 3.5% [1]

Group 1 - The company Baicheng Pharmaceutical (SZ 301096) announced that several directors and senior management personnel plan to reduce their shareholdings through centralized bidding within three months after 15 trading days from the announcement date [1][2] - Director Jia Fei plans to reduce his holdings by up to 12,200 shares, accounting for 0.0112% of the total share capital [1] - Director Song Bofan plans to reduce her holdings by up to 2,300 shares, accounting for 0.0021% of the total share capital [1] - Director Yan Hongbing plans to reduce his holdings by up to 9,500 shares, accounting for 0.0088% of the total share capital [1] - Senior management Chen An plans to reduce his holdings by up to 11,200 shares, accounting for 0.0103% of the total share capital [2] Group 2 - As of the announcement, Baicheng Pharmaceutical's market capitalization is 6.8 billion yuan [3] - For the first half of 2025, the revenue composition of Baicheng Pharmaceutical is as follows: CRO business accounts for 86.22%, commercial production accounts for 10.28%, and CDMO business accounts for 3.5% [2]

Core Viewpoint - Baicheng Pharmaceutical (301096.SZ) plans to participate in the subscription of shares in West Lake Innovation (Hangzhou) Venture Capital Partnership, focusing on investment in strategic emerging industries such as biomedicine and hard technology [1] Group 1 - The company will invest 15 million yuan through its controlled entity, Hangzhou Mipeng Enterprise Management Partnership [1] - The partnership aims to target early-stage, small to medium-sized, and growth-stage enterprises for investment opportunities [1]

Core Viewpoint - The announcement from Baicheng Pharmaceutical indicates that four shareholders plan to reduce their holdings due to personal financial needs, which may impact the company's stock performance in the short term [1] Shareholder Reduction Plans - Shareholder Jia Fei intends to reduce his holdings by no more than 12,200 shares, representing 0.0112% of the company's total share capital [1] - Shareholder Song Bofan plans to reduce his holdings by no more than 2,300 shares, which accounts for 0.0021% of the total share capital [1] - Shareholder Yan Hongbing aims to reduce his holdings by no more than 9,500 shares, equivalent to 0.0088% of the total share capital [1] - Shareholder Chen An is set to reduce his holdings by no more than 11,200 shares, making up 0.0103% of the total share capital [1] Implementation Timeline - The reduction plans will be executed within three months starting from 15 trading days after the announcement date, with specific timing and pricing remaining uncertain [1]

Core Viewpoint - Baicheng Pharmaceutical (301096.SZ) plans to participate in the subscription of shares in West Lake Innovation (Hangzhou) Venture Capital Partnership, focusing on investment in strategic emerging industries such as biomedicine and hard technology [1] Group 1 - The company will invest 15 million yuan through its controlled entity, Hangzhou Mipeng Enterprise Management Partnership [1] - The partnership aims to target early-stage, small to medium-sized, and growth-stage enterprises for investment opportunities [1]

Core Points - Baicheng Pharmaceutical announced that its board member and senior executive Jia Fei holds 48,908 shares, accounting for 0.0451% of the total shares, and plans to reduce his holdings by no more than 12,200 shares, which represents 0.0112% of the total shares [1] - Board member Song Bofan holds 9,337 shares, accounting for 0.0086%, and intends to reduce his holdings by no more than 2,300 shares, which is 0.0021% of the total shares [1] - Board member Yan Hongbing holds 38,145 shares, accounting for 0.0352%, and plans to reduce his holdings by no more than 9,500 shares, representing 0.0088% of the total shares [1] - Senior executive Chen An holds 45,000 shares, accounting for 0.0415%, and intends to reduce his holdings by no more than 11,200 shares, which is 0.0103% of the total shares [1]